1. A new perspective on proteinuria and drug therapy for diabetic kidney disease
- Author
-
Ruimin Zhang, Qian Wang, Yaqing Li, Qihu Li, Xuefeng Zhou, Xiangmei Chen, and Zheyi Dong
- Subjects
diabetic kidney disease ,proteinuria ,pathophysiological mechanism ,drug therapy ,Chinese patent medicine ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Diabetic kidney disease (DKD) is one of the leading causes of end-stage renal disease worldwide and significantly increases the risk of premature death due to cardiovascular diseases. Elevated urinary albumin levels are an important clinical feature of DKD. Effective control of albuminuria not only delays glomerular filtration rate decline but also markedly reduces cardiovascular disease risk and all-cause mortality. New drugs for treating DKD proteinuria, including sodium-glucose cotransporter two inhibitors, mineralocorticoid receptor antagonists, and endothelin receptor antagonists, have shown significant efficacy. Auxiliary treatment with proprietary Chinese medicine has also yielded promising results; however, it also faces a broader scope for development. The mechanisms by which these drugs treat albuminuria in patients with DKD should be described more thoroughly. The positive effects of combination therapy with two or more drugs in reducing albuminuria and protecting the kidneys warrant further investigation. Therefore, this review explores the pathophysiological mechanism of albuminuria in patients with DKD, the value of clinical diagnosis and prognosis, new progress and mechanisms of treatment, and multidrug therapy in patients who have type 2 diabetic kidney disease, providing a new perspective on the clinical diagnosis and treatment of DKD.
- Published
- 2024
- Full Text
- View/download PDF